This is the first in a two-part series on coenzyme Q10,
which is sometime referred to as The Miracle Nutrient.
In fact, The Miracle Nutrient: Coenzyme Q10 is the title
of a book that was written by Emile Bliznakov, MD, who was
one of the first scientists to research and report the benefits
of coenzyme Q10 to the non-scientific population of the world.
CoQ10 has been known of for 60 years. There are two forms: an
oxidized form (Ubiquinone) and a reduced form (Ubiquinol).
The ubiquinol form is unstable and has only been in the USA
market since 2006. The ubiquinone form had been in the USA
market since 1974. Ubiquinol is poorly researched while there
are more than 2000 scientific articles on ubiquinone.
Coenzyme Q10 or CoQ10, was discovered by biochemist
Fred Crane at the University of Wisconsin in 1957. Coenzyme
Q10 is a yellow crystalline substance that belongs to a class of
compounds called quinones. Since all living things create some
form of this compound for energy production, it was given the
chemical name ubiquinone, which is a contraction of ubiquitous
(meaning everywhere) and quinone.
Dr. Crane sent a sample of the yellow crystals he had isolated
from beef heart mitochondria to Dr. Karl Folkers for analysis
and confirmation. At the time, Folkers was a leading biochemist
at the pharmaceutical company Merck, Sharpe and Dohme.
In 1958, Dr. Folkers determined the exact structure of CoQ10 and conducted some preliminary studies, which suggested that
CoQ10 had enormous potential as a cardiovascular drug.
When Folkers made his recommendations to Merck’s top
management, they were not interested because Merck had
recently launched a new blood pressure-lowering drug named
Diuril. Since Merck had already trained their drug sales force
and committed a huge budget to marketing and advertising
Diuril, they did not want to introduce another cardiovascular
drug into the marketplace that would compete with their own
newly launched drug. Subsequently, Merck sold the patents
rights on CoQ10 to a Japanese firm.
It took the Japanese about ten years to learn how to develop
the technology that enabled the production of pure coenzyme
Q10 in quantities that were adequate to support clinical trials in
heart failure patients in Japan. During this ten year development
time period, some small trials revealed that the ubiquinol form
of CoQ10 was also a powerful antioxidant. As an energizer and
an antioxidant, CoQ10 was found to be an effective natural
product for the management of individuals with congestive
heart failure.
Coenzyme Q10 and Energy Production:
Coenzyme Q10 in the oxidized form (ubiquinone) is required
for energy production in the mitochondria of all cells except the
red blood cells. Specifically, CoQ10 is required in several steps
of what is called the electron transport chain in mitochondrial
inner membranes, which is where cellular energy, knows as ATP,
is produced. In the 1960s, biochemist Peter Mitchell, Ph.D. first
put forth his theories on how coenzyme Q10 participates in
and is required for energy production in mitochondria. In 1978,
Dr. Mitchell was awarded the Nobel Prize in Chemistry for his
discovery. Peter Mitchell is still recognized as the scientist who
revolutionized coenzyme Q10 research and educated the world
about CoQ’s central role in the production of energy in all living
organisms.
Coenzyme Q10 deficiency and the resulting decline in
energy production quickly affects systems in the body that have
high metabolic energy requirements such as the lungs, kidneys,
brain, immune system and muscles. Yes, especially muscles.
Since the heart is the most energy-demanding muscle in the
body, one of the first effects of CoQ10 deficiency is a weakening
of the heart.
Coenzyme Q10 Deficiency And Congestive Health Failure:
Because CoQ10 deficiency reduces the ability of the heart to
generate energy, some of the first observations regarding this
newly discovered nutritional substance were that patients
with congestive heart failure had low levels of coenzyme Q10.
Based on these early findings, some of the first clinical trials
with CoQ10 involved patients with chronic heart failure, which
is also known as congestive heart failure. And, CoQ10 therapy
in patients with heart disease turned out to be ASTOUNDINGLY
successful. In fact, the author of one study felt compelled to call
CoQ10 therapy a scientific breakthrough in the management of
chronic heart failure.1
Initially, coenzyme Q10 was introduced in Japan as
a prescription drug for the treatment of various forms of
cardiovascular disease. It remained one of the top-selling
cardiovascular drugs in Japan for over twenty years. In 1991
coenzyme Q10 was taken off prescription drug status and
made available as an over-the-counter product to the general
public. Almost immediately, use of CoQ10 in Japan skyrocketed,
which caused a world-wide shortage of supply and resulted in a
substantial increase in its price.
Coenzyme Q10: A Critical Antioxidant
Coenzyme Q10 in the reduced form (Ubiquinol) is a fat-soluble
antioxidant that is made in all cells throughout the body. In
fact, CoQ10 is the ONLY fat-soluble antioxidant that is made
in the body, which results from the enzymatic conversion of
ubiquinone to ubiquinol. CoQ10’s (Ubiquinol) most important
functions are its ability to inhibit oxidative free radical damage
to the fats that comprise the structure of cellular membranes
throughout the body.2
For decades cardiologists have prescribed statin drugs in
the belief that elevated LDL-cholesterol is a major risk factor for
cardiovascular disease. There is increasing skepticism regarding
the level of risk associated with elevated LDL-cholesterol and
the frequent prescribing of statins. However, it is well accepted
that when LDL-cholesterol undergoes free radical damage, it
becomes a “damaged” molecule that is referred to as oxidized
LDL-cholesterol. Oxidized LDL-cholesterol is capable of causing
damage to the lining of the blood vessels. In a simplification
of a complex process, we can simply say that the body creates
plaque deposits in an effort to repair this damage. So, it is really
oxidized LDL-cholesterol that initiates plaque build-up and
increases the risks of heart attacks and strokes.
In a 1997 study on coenzyme Q10 and statin drugs,
cardiologist Svend Mortensen made the following important
statement. Dr. Mortensen announced that CoQ10 is an
antioxidant that is “packaged into the LDL & VLDL fractions
of cholesterol.” This means that the LDL cholesterol molecule
is the primary method by which coenzyme gets transported
around the body. Thus, when CoQ10 is being transported on
the LDL cholesterol molecule, CoQ10’s antioxidant properties
enable it to protect LDL cholesterol against oxidative damage.
This is one way that CoQ10 reduces cardiovascular disease
risks.3
Coenzyme Q10 Lowers Elevated Blood Pressure
In 1980, Dr. Folkers reported treating 16 patients with high
blood pressure (10 already taking BP meds and 6 untreated)
with CoQ10 14 of 16 patients achieved significant lowering of
systolic blood pressure and 11/16 achieved significant lowering
of diastolic blood pressure. In the patients who had elevated
blood pressure even though they were taking BP-lowering
drugs, 9 of 10 achieved reductions that brought their blood
pressure readings into the normal range.4
Another study that demonstrates coenzyme Q10’s blood
pressure lowering ability was conducted by cardiologist Peter
Langsjoen. He selected 109 of his patients with hypertension
and added CoQ10 (average dose was 225 mg/day) to their
existing medications. The average time of from initial diagnosis
was 9.2 years and many patients were taking two or three blood
pressure-lowering medications to keep their pressure within
the acceptable range. Within six months of initiating high-dose
CoQ10 therapy, 55 of 109 (51 percent) of the patients experienced
reductions in their blood pressure readings that enabled them
to discontinue taking their blood pressure medications.5
More recently, a meta-analysis of 12 clinical trials reported
that CoQ10 lowered systolic blood pressure by 17 points and
it lowered diastolic blood pressure approximately 10 points.6
Thus, the blood pressure lowering effect of coenzyme Q10 is
sufficient to keep hundreds of thousands of individuals with
borderline hypertension from having to take blood pressurelowering
medications.
The FDA Inhibits Education
Utilization of coenzyme Q10 in the United States has lagged
behind that of Japan and European countries for several
reasons. Nearly 2,000 studies have been published in which
either coenzyme Q10 or CoQ10 appear in the title of the study.
However, in the United States, FDA policy prohibits nutritional
supplement companies from making ANY reference to ANY
health claims regarding a nutritional product. This greatly
inhibits the public's access to educational information about
the benefits of nutritional supplements. Also, pharmaceutical
companies are not interested in promoting information about
CoQ10 or CoQ10 products because it is a natural product,
which means a drug company cannot have an exclusive
patent on it. Another reason drug companies don't want
the word to get out about coenzyme Q10 is the fact that it is
SAFER and MORE EFFECTIVE than most cardiovascular drugs
on the market, which is a multi-billion-dollar market for the
pharmaceutical industry.
Coenzyme Q10 And Statin Drugs:
In 1987 the FDA approved the first statin drug named lovastatin,
which was marketed by Merck under the brand name Mevacor.
Statins work by blocking an enzyme in the liver named HMGCoA
reductase, which is required for the biosynthesis of
cholesterol. When a statin drug blocks HMG-CoA reductase,
the synthesis of cholesterol is inhibited and cholesterol blood
levels decline fairly rapidly.
Lovastatin's success at lowering cholesterol levels resulted
in other drug companies bringing their version of a statin
drug to the market. Statin drugs became a "goldmine" for the
pharmaceutical industry. There are currently seven statin drugs
available in the United States and statins became one of the
best-selling classes of drugs in history. In 2011, global sales of
statin drugs exceeded $39 billion. Also, in 2009 and 2010, Lipitor
(atorvastatin) was ranked as the #1 selling drug in the world with
2009 sales of $11 billion and 2010 sales of $10 billion.
The Dark Side of Statin Drugs:
It is estimated that about 32 million Americans (about 25
percent of people aged 45 and older) are taking statin drugs.
In February 2016, The FDA mandated the addition of new
warnings regarding potential statin drug side effects which
include increased risks of liver damage, confusion and memory
loss, type 2 diabetes and muscle weakness.
One of the most serious side effects of statin drugs is
something that the FDA has still refused to address. The
HMG-CoA reductase enzyme that is critical for cholesterol
synthesis is also required for the synthesis of coenzyme Q10.
Multiple studies document the fact that in addition to lowering
cholesterol levels, statin drug therapy also causes a dramatic
decline in coenzyme Q10 levels.7,8
Drugs That Deplete Coenzyme Q10:
In addition to statins, the following other classes of commonly
prescribed drugs deplete coenzyme Q10; oral contraceptives,
hormone replacement therapy (HRT), oral hypoglycemic drugs
such as metformin for the treatment of type 2 diabetes, thiazide
diuretics, beta-blockers and tricyclic antidepressants. Because
they inhibit the production of CoQ10, these drugs induce low
energy syndromes resulting in reduced muscle function.
Next month, in Part 2 of this series we will discuss coenzyme Q10's
role in the prevention and treatment of cancer and various other
diseases, its function as an effective anti-aging nutrient, and issues
related to CoQ10 recrystallization and the relative absorption and
effectiveness of various CoQ10 products on the market.
References
- Morensen SA. Coenzyme Q10: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure. Int J Tissue Teact. 1990;12(3):155¡V 62.
- Littarru GP, Bioenergetic and Antioxidant Properties of Coenzyme Q10: Recent Developments. Molecular Biotechnology. Sept. 2007; 37(1):31-7.
- Mortensen SA. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med. 1997;18 Suppl:S137-44.
- Folkers K. Bioenergetics in clinical medicine. XVI. Reduction of hypertension in patients bytherapy with coenzyme Q10. Res Comm Chem Pathol Pharmacol. 1981 Jan;31(1):129-40.
- Langsjoen P. Treatment of essential hypertension with coenzyme Q10. Mol Aspects Med. 1994;15 Supp:S265-72.
- Rosenfeldt FL, el al. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension. 2007 apr;21(4):297-306.
- Mortensen SA. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med. 1997;18 Suppl:S137-44.
- G. Ghirlanda, et al., "Evidence of Plasma CoQ10-lowering Effect by HMGCoA Reductase Inhibitors: A DB PC Study," J Clin Pharmacol. March 1993; 33(3): 226-9